Presented here is a protocol for non-invasive mesenchymal stem cell (MSC) delivery and tracking in a mouse model of traumatic brain injury. Superparamagnetic iron oxide nanoparticles are employed as a magnetic resonance imaging (MRI) probe for MSC labeling and non-invasive in vivo tracking following intranasal delivery using real-time MRI.
Stem cell-based therapies for brain injuries, such as traumatic brain injury (TBI), are a promising approach for clinical trials. However, technical hurdles such as invasive cell delivery and tracking with low transplantation efficiency remain challenges in translational stem-based therapy. This article describes an emerging technique for stem cell labeling and tracking based on the labeling of the mesenchymal stem cells (MSCs) with superparamagnetic iron oxide (SPIO) nanoparticles, as well as intranasal delivery of the labeled MSCs. These nanoparticles are fluorescein isothiocyanate (FITC)-embedded and safe to label the MSCs, which are subsequently delivered to the brains of TBI-induced mice by the intranasal route. They are then tracked non-invasively in vivo by real-time magnetic resonance imaging (MRI). Important advantages of this technique that combines SPIO for cell labeling and intranasal delivery include (1) non-invasive, in vivo MSC tracking after delivery for long tracking periods, (2) the possibility of multiple dosing regimens due to the non-invasive route of MSC delivery, and (3) possible applications to humans, owing to the safety of SPIO, non-invasive nature of the cell-tracking method by MRI, and route of administration.
Mesenchymal stem cells (MSC) are attractive candidates for stem cell-based therapies in treatments of central nervous system (CNS) disorders and injuries in humans. Moreover, MSCs have been used as a vehicle for the delivery of therapeutic proteins at injury sites1,2. In recent years, promising innovations have been developed to establish 1) novel routes of cell delivery and 2) cell tracking for stem cell-based therapies of CNS disorders. The intranasal delivery of stem cells into the brain depends on the ability of cells to bypass the cribriform plate and enter the olfactory bulb partially via a parenchymal route3. The combination of intranasal delivery and the labeling of MSCs with superparamagnetic iron oxide (SPIO) nanoparticles represents a promising approach for clinical applications of MSCs in treating CNS disorders, since SPIO nanoparticles are safe probes for magnetic resonance imaging (MRI) and allow non-invasive sensitive longitudinal tracking of MSCs post-delivery by MRI3,4,5. Furthermore, intranasal delivery is a safe and non-invasive route that allows repeated administration within a short period of time.
This article describes a highly sensitive and non-invasive technique for tracking MSCs in vivo post-intranasal delivery in a mouse model of traumatic brain injury (TBI), which employs SPIO-labeled cells and MRI. One important advantage of the SPIO labeling is the sensitive detection of SPIO in tissue by MRI, which makes it possible to track cells efficiently and non-invasively. The SPIO nanoparticles used here are commercially available and tagged with a fluorescein isothiocyanate (FITC) fluorophore, which allows for the detection of SPIO in tissue without immunostaining or additional processing. Furthermore, it is possible to perform longitudinal real-time tracking and investigate the biodistribution of the delivered MSCs.
All procedures involving animals in this protocol were approved by the Institutional Animal Care and Use Committee, with the approval of the Ethics Committee for animal use in Taipei Medical University (approval no. LAC-2018-0574; 15.03.2019).
1. Labeling of MSCs with SPIO Nanoparticles
2. Controlled Cortical Impact (CCI) Injury
NOTE: In this protocol, male C57 BL/6 mice (7–8 weeks old) were kept in a 12/12 h light/dark cycle with ad libitum access to food and water.
3. Intranasal Delivery
4. In Vivo Magnetic Resonance Imaging
NOTE: Histological staining of brain tissue has previously been used to confirm the successful delivery of stem cells after intranasal administration. However, this method can only be used as an endpoint of a study, not longitudinally. Using MRI probes to label therapeutic stem cells will allow for longitudinal, non-invasive, in vivo tracking of the cells using MRI. Importantly, this protocol efficiently reduces the number of animals required. In this protocol, MRI scanning was performed at days 1, 7, and 14 post-delivery of MSCs.
5. Fixation of the Mouse Brain and Cryosectioning
6. Prussian Blue Staining
NOTE: Prussian blue staining is commonly used to detect the iron content in SPIO-labeled cells. Here, Prussian blue staining is used to confirm that the hypointense signals in the MRI images correspond to the SPIO-labeled MSCs and not to artifacts. Prussian blue staining is one of the most sensitive histochemical methods used to detect iron in tissues and can be used to identify even a single granule of iron in the cells.
Twenty-four hours following intranasal delivery, the SPIO-labeled MSCs were detected as strong hypointense areas medial to the cortical injury on T2*-weighted images (Figure 2B), indicating the targeted migration of SPIO to the injury site. This migration remained visible up to 14 days post-delivery, as the hypointense signals were found to be visible without significant reduction for this time period (Figure 2B). The injured animals treated with PBS showed no hypointense areas, indicating that the observed hypointense areas correspond to the SPIO labeled MSCs and not to signal artifacts (Figure 2A) The biodistribution of the labeled MSCs that were observed in vivo with MRI was visualized using 3D reconstruction (Figure 2C,D). The migration of MSCs to the injured cortex was confirmed histologically by Prussian blue staining and FITC channel detection of the FITC-tagged SPIO in the labeled MSCs (Figure 3A,B).
Figure 1: Schematic flowchart of the protocol and in vitro confirmation of SPIO uptake by MSCs. (A) MSCs were incubated with SPIO for 24 h for labeling. Then, the labeled MSCs were delivered into a TBI mouse model via an intranasal (IN) route. MRI at different timepoints was performed to track the labeled MSCs. Confirmation of sufficient labeling of MSCs by SPIO was achieved by (B) fluorescence microscopy and (C) confocal microscopy using the FITC channel, since SPIO nanoparticles were tagged with FITC. (D) The cell pellet of the labeled MSCs appeared dark in color due to iron loading. FITC = fluorescein isothiocyanate; SPIO = superparamagnetic particles of iron oxide; MSCs = mesenchymal stem cells; MRI = magnetic resonance imaging; IN = intranasal; TBI = traumatic brain injury. Please click here to view a larger version of this figure.
Figure 2: Real-time MRI enables the detection and tracking of SPIO-labeled MSC migration toward injury sites in the brains of TBI-induced mice. (A) Mice were subjected to TBI, followed by treatment with PBS or SPIO-labelled MSCs, administered via an intranasal route 24 h after injury. Coronal sections of T2*-weighted images showed the labeled MSCs as a hypointense area (arrowhead) on the edge of the injury site (outlined area) at 1, 7, and 14 days post-delivery. The PBS-treated mice show no hypointense area. (B) Segmentation process of the injury site area (green) and labeled MSCs (red) based on coronal T2*-MRI images. (C) 3D reconstruction of the mouse brain treatment based on T2*-weighted images illustrating the biodistribution of SPIO-labeled MSCs in the brain 14 days post-delivery. Please click here to view a larger version of this figure.
Figure 3: Histological analysis confirms the presence of SPIO-labeled MSCs in the brains of the treated animals. Prussian blue staining of brain sections of a (A) mouse treated with PBS (control) and (C) mouse treated with SPIO-labeled MSCs. SPIO-positive cells were detected in MSC-treated mouse (boxed cells, blue), while the control mouse showed no positive cells at the injury site in the cortex at 14 days post-delivery, confirming MRI observations. Fluorescence microscopy analysis of the cortex of a (B) control mouse treated with PBS and (D) mouse treated with SPIO-labeled MSCs was conducted 14 days post-delivery. The analysis revealed the presence of FITC-tagged SPIO-positive cells (boxed cells, green) at the injured cortex in the MSC-treated mouse, but no FITC signals were observed in the cortex of the PBS-treated mouse. Scale bars = 50 µm, unless stated otherwise. Please click here to view a larger version of this figure.
The protocol described here represents general procedures for the SPIO labeling of MSCs and MRI tracking of SPIO-labeled MSCs post-intranasal delivery. The protocol allows the opportunity to study the migration and biodistribution of MSCs post-delivery in vivo in the brain, using a non-invasive method.
MSCs are attractive candidates for stem cell-based therapies for CNS disorders and injuries due to their ability to secrete trophic factors that 1) trigger neurorestorative processes and 2) provide neuroprotection, owing to their anti-inflammatory effects within the injury area9,10,11,12. Although long-term MRI tracking and detection of SPIO-labeled MSCs may be limited due to the dilution of intercellular SPIO with cell division, labeled cells can be detected for up to several weeks post-transplantation in the brains of animal models13.
Also described here is the labeling protocol of MSCs with SPIO nanoparticles coated with dextran without transfection agents. Other protocols have been used in the literature14,15,16. However, in all cases, these protocols should be adjusted for cell type, SPIO size, incubation time, and SPIO concentration. MSCs have been shown to have impaired chondrogenic differentiation potential but not adipogenic differentiation upon SPIO labeling17. Therefore, it is highly recommended that differentiation assays be performed prior to stem cell delivery to evaluate the influence of SPIO on the differentiation potency of stem cells. In a previous study, it was demonstrated that MSC labeling with the same SPIO type and concentration used in the here did not affect the osteogenic or adipogenic differentiation potency of MSCs6.
The intranasal route of therapeutic stem cell delivery for brain disorders and injuries is a promising approach for the clinical application of stem cells. However, the intrinsic and molecular mechanisms that dictate the behaviors of stem cells in the nasal cavity remain unclear. Although the intranasal route is widely explored for the delivery of small molecules, the size and biodistribution behavior of the therapeutic stem differ from small molecules. The current protocol demonstrates that MSCs tend to migrate toward the injury site after intranasal delivery.
Here, T2*-weighted images were used to track the SPIO-labeled MSCs. Other reports have used gradient echo imaging. However, susceptibility artefacts are often observed in gradient echo imaging due to intercellular SPIO. In the current protocol, the location of the hypointense areas representing the SPIO-labeled MSCs on T2*-weighted images was the same as the location of the SPIO in brain sections as detected by histological examination (Figure 3). This indicates the adequate sensitivity of T2*-weighted spin echo imaging for SPIO-labeled MSC tracking in the brain.
In summary, the described protocol is beneficial for in vivo stem cell tracking studies of brain injuries and disorders. The longitudinal tracking of stem cells in vivo has traditionally been performed by sacrificing animals at multiple timepoints. The current protocol provides a non-invasive and efficient approach for MSCs delivery and tracking, which represents a potential procedure for stem cell-based therapy for brain injuries and disorders in clinical settings.
The authors have nothing to disclose.
This work was supported by the Ministry of Science and Technology Grants, Taiwan (MOST 104-2923-B-038-004 -MY2, MOST 107-2314-B-038-063, and MOST 107-2314-B-038-042) and Taipei Medical University (TMU 105-AE1-B03, TMU 106-5400-004-400, TMU 106-5310-001-400, DP2-107-21121-01-N-05 and DP2-108-21121-01-N-05-01).
Cell culture supplies (Plastics) | ThermoFisher Scientific | Varies | Replaceable with any source |
Disposable Microtome Blade | VWR | 95057-832 | |
D-MEM/F-12 (1X) with GlutaMAX | GIBCO | 10565-018 | |
Embedding medium for frozen tissue specimens (O. C. T.) | Sakura Finetek | 4583 | |
Fetal Bovine Serum (FBS) | GIBCO | 12662-029 | |
Fluorescence Wild Field Microscope | Olympus | Olympus BX43 | |
Forcept | Fine Science Tools | 11293-00 | Surgery |
Gentamicin (10 mg/mL) | GIBCO | 15710-064 | |
Hair clipper | Pet Club | PC-400 | |
Head Trauma Contusion device | Precision Systems and Instrumentation | Model TBI-0310 | |
Hyaluronidase from bovine testes | MilliporeSigma | H3506 | |
ITK-SNAP Software | Penn Image Computing and Science Laboratory (PICSL) at the University of Pennsylvania, and the Scientific Computing and Imaging Institute (SCI) at University of Utah | ITK-SNAP 3.8.0 | |
Ketamine (Ketavet) | Pfizer | 778-551 | |
Mice | National Laboratory Animal Center, Taiwan | C57BL6 | Wild type mice strain used in the study |
Microdrill | Nakanishi | NE50 | Combine with Burrs for generating the bone window |
Microtome | Leica | RM2265 | |
Mouse (C57BL/6) Mesenchymal Stem Cells | GIBCO | S1502-100 | |
MRI scanner | Bruker Biospec | ||
Phosphate Buffer Saline (PBS) | Corning Cellgro/ThermoFisher | 21-031-CV | |
Povidone-iodine 7.5% | Purdue product L.P. | Surgical scrub | |
Prussian Blue Stain | Abcam | ab150674 | |
Scissor | Fine Science Tools | 14084-08 | Surgery |
Stereotaxic frame | Kopf Instruments | Model 900 | |
Superparamagnetic iron oxide (SPIO) nanoparticles | BioPAL | Molday ION EverGreen, CL-50Q02-6A-51 | stem cells labeling for in vivo tracking using MRI |
Suture monofilament | Ethicon | G697 | Suture |
Timer | Wisewind | Replaceable with any source | |
TrypLE | GIBCO | 12604-013 | |
Xylazine (Rompun) | Bayer | QN05 cm92 |